BeiGene, Ltd.
-
Ticker
BGNE
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 1001-5000 Employees
- Based in Cambridge, Massachusetts
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Their 4,200+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics
…More. They currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. They also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma.
REPORT RATINGS
4.8 / 5.0 (86)
BeiGene, Ltd. reports have an aggregate usefulness score of 4.8 based on 86 reviews.
BeiGene, Ltd.
Most Recent Responsibility Report
MOST RECENT
2023 Environmental, Social, and
Governance (ESG) Report
Archived Responsibility Reports
Our service enables potential investors to review the most recent and archived BeiGene, Ltd. Sustainability Report, BeiGene, Ltd. Corporate Social Responsibility Report, BeiGene, Ltd. CSR Report, BeiGene, Ltd. Corporate Responsibility, BeiGene, Ltd. CR Report, BeiGene, Ltd. Citizenship Report, BeiGene, Ltd. ESG Report, and BeiGene, Ltd. Environmental Report online.